

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Distribution of nephrologists and regional variation in the clinical severity of IgA nephropathy at biopsy diagnosis in Japan: A cross-sectional ecological study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024317
Article Type:	Research
Date Submitted by the Author:	05-Jun-2018
Complete List of Authors:	Okabayashi, Yusuke; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine Tsuboi, Nobuo; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine Amano, Hoichi; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine Miyazaki, Yoichi; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine Kawamura, Tetsuya; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine Ogura, Makoto; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine Narita, Ichiei; Niigata University Medical and Dental Hospital, Department of Medicine (II) Toshiharu, N; Kyushu University, Fukuoka, Japan, Department of Epidemiology and Public Health Yokoyama, Hitoshi; Kanazawa Medical University School of Medicine Graduate School of Medicine Department of Nephrology, Department of Nephrology Yokoo, Takashi; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine
Keywords:	IgA nephropathy, regional differences, renal biopsy, proteinuria

SCHOLARONE™
Manuscripts

1
2
3
4 **Distribution of nephrologists and regional variation in the clinical severity of IgA nephropathy**
5
6
7 **at biopsy diagnosis in Japan: A cross-sectional ecological study**
8
9
10
11
12

13 Yusuke Okabayashi, MD¹; Nobuo Tsuboi, MD, PhD¹; Hoichi Amano, MD¹; Yoichi Miyazaki, MD,
14
15
16 PhD¹; Tetsuya Kawamura, MD, PhD¹; Makoto Ogura, MD, PhD¹; Ichiei Narita, MD, PhD²;
17
18
19 Toshiharu Ninomiya, MD, PhD³; Hitoshi Yokoyama, MD, PhD⁴; Takashi Yokoo, MD, PhD¹
20
21
22
23
24
25

26 ¹) Division of Nephrology and Hypertension, The Jikei University School of Medicine
27

28
29 ²) Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of
30
31
32 Medical and Dental Sciences
33

34
35 ³) Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu
36
37
38 University
39

40
41 ⁴) Department of Nephrology, Kanazawa Medical University School of Medicine
42
43
44
45
46
47

48 **Running title:** Regional variation of IgA nephropathy in Japan
49

50
51 **Word count:** 3247, abstract: 294
52
53

54 **Key words:** IgA nephropathy, regional differences, nephrologist, renal biopsy, proteinuria
55
56
57

1
2
3
4 **Correspondence to:** Nobuo Tsuboi, M.D., Ph.D.
5

6
7 Division of Nephrology and Hypertension, Department of Internal Medicine,
8

9
10 The Jikei University School of Medicine, Tokyo 105-8641, Japan
11

12
13 3-25-8 Nishi-Shinbashi, Minato-Ku,
14

15
16 Tel: 81-3-3433-1111, Fax: 81-3-3433-4297, E-mail: tsuboi-n@jikei.ac.jp
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: The clinical severity of IgA nephropathy (IgAN) at the time of biopsy diagnosis differs significantly among cases. One possible determinant of any such difference is the time taken for referral from the primary care physician to a nephrologist, but the definitive cause remains unclear.

This study examined the contribution of the number of nephrologists per regional population as a potential social factor influencing the clinical severity at diagnosis among IgAN patients in Japan, which has an ethnically homogeneous population.

Design: A cross-sectional ecological study.

Setting & participants: Patients were registered in the Japan Renal Biopsy Registry (J-RBR), a nationwide multicenter registry, and 6426 patients diagnosed with IgAN were analyzed. The facilities registered to the J-RBR were divided into 10 regions and the clinical features of IgAN at biopsy diagnosis, including renal function, level of proteinuria were examined.

Main outcome measures: Renal prognosis risk at the time of biopsy diagnosis defined by Kidney Disease Improving Global Outcomes guideline 2012.

Results: Among the regions, there were significant differences in the estimated glomerular filtration rate (67.5–91.4 ml/min/1.73 m²), urinary protein excretion rate (0.93–1.93 g/day), and renal prognosis risk group distribution at diagnosis. The severity of all clinical parameters was inversely

1
2
3
4 correlated with the number of nephrologists per regional population, which showed an up to 2.7-fold
5
6
7 difference among regions. A generalized linear mixed model revealed that a low number of
8
9
10 nephrologists per regional population was significantly associated with fulfilment of clinical criteria
11
12
13 indicating a very-high-risk renal prognosis ($\beta = -0.484$, 95% CI -0.959 to -0.010).
14
15

16 **Conclusions:** Among Japanese patients with IgAN, significant regional differences were detected in
17
18
19 clinical severity at the time of diagnosis. Social factors, such as an uneven distribution of
20
21
22 nephrologists across regions, may influence the timing of biopsy and determine such differences.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article Summary

Strengths and limitations of this study

- This is the first reported study to reveal regional differences in the clinical severity of the patients with IgA nephropathy (IgAN) at biopsy diagnosis in Japan.
- Lower number of nephrologists per regional population in Japan was associated with an increase in the frequency of clinical criteria indicating the very-high-risk renal prognosis of IgAN patients in each region, which was determined by renal function and amount of proteinuria at the time of biopsy diagnosis.
- The uneven regional distribution of nephrologists may influence the time taken for referral to a nephrologist and the likelihood of earlier interventions in IgAN patients.
- Japan is one of only a few countries in the world that screen for kidney diseases by urinalysis, thus the applicability of the findings to countries other than Japan is unclear.

Introduction

IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis and a major cause of end-stage renal disease (ESRD) worldwide [1,2]. Impaired renal function and severe proteinuria at presentation are among the strongest predictors of a poor renal prognosis in patients with IgAN [3-5]. Advanced age, hypertension, male gender, obesity, and absence of gross hematuria are considered poor prognostic indicators, although controversy exists in the degree of involvement of these factors, which varies by study depending on the subject characteristics [6-8]. Previous studies have shown racial/ethnic differences in the prevalence of IgAN, and the relative number of patients diagnosed with IgAN is higher in Asian countries than in other countries [9-11]. Recent genome-wide analyses have demonstrated that genetic factors may underlie the diversity in the incidence and severity of IgAN [12-15].

Except for cases showing gross hematuria, the onset of IgAN is often asymptomatic [16]. In addition, IgAN cannot be diagnosed unless a renal biopsy is performed, as deposition of IgA in glomeruli can be demonstrated histopathologically. Social factors, such as the penetration rate of urinalysis screening for kidney disease or the time taken for referral from the primary care physician to a nephrologist, may considerably influence the latency to IgAN diagnosis. In fact, in most patients in Japan, IgAN is first identified at a health checkup, followed by referral to a nephrologist [17,18].

1
2
3
4 Such differences in survival related to the duration of disease at time of presentation rather than true
5
6
7 variability in disease severity is called lead-time bias, and may be associated with disease prognosis
8
9
10 in IgAN patients [19].
11
12

13 Few studies have focused on regional variation in the clinical characteristics of IgAN [13,15].
14
15

16 In addition, other than race/ethnicity, no factors that may affect such regional variation in disease
17
18
19 severity have been determined. In this study, we analyzed patients with IgAN in Japan, which has an
20
21
22 ethnically homogeneous population [20]. Social factors that may affect the biopsy diagnosis of IgAN
23
24
25 were examined in the context of potential differences in the clinical severity of IgAN among various
26
27
28 regions of Japan.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Materials and Methods

Registry system and patient selection

The Japan Renal Biopsy Registry (J-RBR) is a nationwide, multicenter registry system, which was established in 2007 by the Committee for Standardization of Renal Pathological Diagnosis and the Working Group for the Renal Biopsy Database of the Japanese Society of Nephrology (JSN) [21]. This cross-sectional ecological study included Japanese patients with primary IgAN registered on the J-RBR from January 1, 2007 through June 30, 2013. During the registration period, 7,970 patients diagnosed with IgAN were included in the J-RBR. Of these 7,970 patients, 1,544 were excluded because of missing data critical for the analysis. A total of 6,426 patients were finally subjected to the analysis. The diagnosis of IgAN was histopathologically determined based on the basic glomerular changes described in the classification of glomerular diseases of the World Health Organization, and by immunohistological identification of IgA in glomeruli [22]. Patients who were diagnosed with other renal or systemic diseases, including those with Henoch–Schönlein purpura, systemic lupus erythematosus, and liver cirrhosis were excluded. Clinical data, including age, sex, body mass index (BMI), systolic and diastolic blood pressure, the presence or absence of hypertension, estimated glomerular filtration rate (eGFR), urinary protein excretion (UPE) rate, urinary sediment, serum albumin, and serum total cholesterol were evaluated.

1
2
3
4 All clinical data were obtained at the time of the diagnostic renal biopsy. Patients with missing data
5
6
7 necessary for the study, such as renal function measurements, the presence or absence of
8
9
10 hypertension and/or the UPE rate, were excluded from the analyses. The J-RBR is registered in the
11
12
13 UMIN Clinical Trials Registry (registered number: UMIN000000618).
14
15

16 17 18 19 *Measurements and definitions* 20

21
22 The J-RBR registration facilities were divided into 10 regions of Japan: Hokkaido, Tohoku,
23
24
25 Kanto, Koshinetsu, Hokuriku, Tokai, Kinki, Chugoku, Shikoku, and Kyusyu (**Figure 1**). The
26
27
28 Japanese populations in these regions are considered ethnically homogeneous [20].
29
30

31
32 The eGFR was calculated using a three-variable equation modified for Japanese populations,
33
34
35 as follows: $eGFR = 194 \times \text{age}^{-0.287} \times \text{sCr}^{-1.094}$ ($\times 0.739$ if female), where sCr is the serum creatinine
36
37
38 concentration [23]. Hematuria was graded based on the number of red blood cells per high power
39
40
41 field in urinary sediment: 1, 2, 3, and 4 for 0–4, 5–10, 11–30, and ≥ 30 , respectively. Hypertension
42
43
44 was defined as a systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg,
45
46
47 according to the Japanese Society of Hypertension Guidelines for the Management of Hypertension
48
49
50 2014 [24], or usage of antihypertensive medications. Patients ≥ 65 years of age were defined as
51
52
53 elderly [25].
54
55
56
57
58
59
60

1
2
3
4 In the Kidney Disease Improving Global Outcomes (KDIGO) 2012 clinical practice guideline
5
6
7 for the evaluation and management of chronic kidney disease, patients with chronic kidney disease
8
9
10 (CKD) are classified into 18 categories and four risk groups (low, moderately increased, high, and
11
12
13 very high risk) based on eGFR and albuminuria categories on a CKD heat map [26]. In Japan, this
14
15
16 CKD risk classification system has been modified according to the cause of kidney disease. Except
17
18
19 for diabetes cases, the UPE rate, instead of the urinary albumin excretion rate, is applied for patients
20
21
22 with CKD including IgAN, based on the requirements of the Japanese national insurance system
23
24
25 [27]. Based on the KDIGO 2012 guidelines, which were modified for the Japanese population, the
26
27
28 UPE rate at the time of biopsy is classified as normal (< 0.15 g/day or g/gCr; A1), mild (0.15–0.49
29
30
31 g/day or g/gCr; A2), or severe (≥ 0.5 g/day or g/gCr; A3) [26,27]. Similarly, eGFR at the time of
32
33
34 biopsy is classified into five groups: G1, G2, G3a, G3b, G4, and G5 for ≥ 90 , 60–89, 45–59, 30–44,
35
36
37 15–29, and < 15 ml/min/1.73 m², respectively. According to the CKD heat map of the 2012 KDIGO
38
39
40 guidelines, which is based on the eGFR level and UPE rate, the renal prognosis is categorized as
41
42
43 low, moderately increased, high, or very high.
44
45
46
47
48
49
50

51 *Social factors*
52
53
54
55
56
57
58
59
60

1
2
3
4 Certain social factors may be associated with regional variation in the clinical features of
5
6
7 IgAN. The first such factor is the number of board-certified JSN nephrologists per regional
8
9
10 population. A qualified JSN board-certified nephrologist must have ≥ 3 years training at a
11
12
13 JSN-accredited facility; have passed a specific exam; and renew their license every 5 years. The
14
15
16 second social factor is the proportion of participants who received a health checkup per regional
17
18
19 population. To ascertain this, we used data from the Specific Health Checkup, a metabolic syndrome
20
21
22 health checkup devised by the Ministry of Health, Labor, and Welfare of Japan that targets people
23
24
25 aged 40–74 years who were enrolled in the national health insurance program in 2012 [28]. The
26
27
28 Specific Health Checkup comprises a physical examination, blood pressure measurement, blood test,
29
30
31 and urinalysis. The third social factor is the proportion of elderly persons relative to the general
32
33
34 population. Information on the proportion of elderly persons (age ≥ 65 years) in each regional
35
36
37 population was obtained from a national survey performed in 2012 [29]. Based on the ranking of the
38
39
40 social factors included in this study, 10 regions of Japan were divided into three groups, as follows:
41
42
43 low (three regions), intermediate (four regions), and high (three regions) groups. Analysis was
44
45
46 performed within each group according to the clinical characteristics of the IgAN patients at the time
47
48
49 of biopsy diagnosis.
50
51
52
53
54
55
56
57
58
59
60

Statistical analysis

Continuous variables are expressed as means \pm standard deviation. Differences among regions were analyzed by the Kruskal–Wallis test. Differences in the characteristics of the IgAN patients within each social factor group were analyzed by the Mantel–Haenszel test for trend and the Jonckheere–Terpstra trend test, as appropriate. A generalized linear mixed model was constructed to identify the social factors that may influence regional variation in the severity of IgAN at the time of biopsy. In each analysis, social factors, age, sex, and the presence or absence of hypertension were treated as fixed covariates, and the regions and the J-RBR registration facilities as random effects. A p-value < 0.05 was considered significant. All statistical analyses were performed using SPSS statistical software (ver. 24.0; IBM, Armonk, NY, USA).

Patient and public involvement

No patient was involved in the design or conduct of the study, since this was a database research study.

Results

Patient clinical characteristics at the time of biopsy diagnosis

The clinical characteristics of the patients at the time of biopsy diagnosis are summarized in **Table 1**. Their mean age was 39.5 years, and 3,297 (51.3%) were males. The mean eGFR was 74.4 ml/min/1.73 m² and the mean UPE rate was 1.16 g/day. A total of 1,813 (28.2%) patients were categorized into the very-high-risk renal prognosis group. The male and female ratio was similar among the 10 regions ($p = 0.182$). On the other hand, significant regional variation was observed in age (32.2–42.5 years, $p < 0.001$), BMI (21.7–23.5 kg/m², $p < 0.001$), prevalence of hypertension (26.8–55.4%, $p < 0.001$), eGFR (67.5–91.4 ml/min/1.73 m², $p < 0.001$), UPE rate (0.93–1.93 g/day, $p < 0.001$), degree of hematuria (frequency of grade 3 or 4 = 51.4–71.5%, $p < 0.001$), and renal prognosis risk group distribution ($p < 0.001$). Notably, there were large differences between the lowest and highest regions with respect to the rates of both very high and low renal prognosis risk, as defined by the KDIGO guidelines (3.66- and 4.92-fold, respectively).

Regional variation in social factors

Variation among the 10 regions in terms of the social factors that may influence the severity of IgAN at biopsy diagnosis were assessed (**Table 2**). The social factors included in this study were

1
2
3
4 the number of board-certified nephrologists, proportion of patients who received a health checkup,
5
6
7 and proportion of elderly persons per regional population. The distributions of these three social
8
9
10 factors differed significantly among the 10 regions. In particular, an up to 2.7-fold among regions
11
12
13 difference was observed in the number of board-certified nephrologists.

14
15
16
17
18
19 *Relationships between social factors and regional variation in the clinical characteristics of the*
20
21
22 *IgAN patients at biopsy diagnosis*
23

24
25
26 Trends in the social factors were analyzed according to regional variation in the clinical
27
28
29 features of the IgAN patients at biopsy diagnosis. The number of nephrologists per regional
30
31
32 population showed a clear trend: the fewer the nephrologists, the more severe were the clinical
33
34
35 features at the biopsy diagnosis, including renal function, the UPE rate, and the renal prognosis risk
36
37
38 distribution (**Table 3**). The regions with higher proportions of IgAN patients with a very-high-risk
39
40
41 renal prognosis and those with fewer nephrologists per regional population showed a similar
42
43
44 distribution trend (**Figure 1**). No such similarities were found between the distribution of IgAN
45
46
47 patients with a very-high-risk renal prognosis and those of health checkup participants or elderly
48
49
50 persons per regional population (**Supplemental Figure 1**).
51
52
53
54
55
56
57
58
59
60

1
2
3
4 A generalized linear mixed model was constructed to examine the relationship between the
5
6
7 three social factors investigated in this study and regional differences in the proportion of IgAN
8
9
10 patients with a very-high-risk renal prognosis at biopsy diagnosis, as defined by the 2012 KDIGO
11
12
13 guidelines. In the model, the number of board-certified nephrologists per regional population was
14
15
16 significantly associated with the rate of fulfilment of the clinical criteria for a very-high-risk renal
17
18
19 prognosis at the biopsy diagnosis, even after considering the differences in clinical factors among
20
21
22 regions (**Table 4, Figure 2**). We did not find a significant relationship between the rate of
23
24
25 very-high-risk renal prognosis at biopsy diagnosis and either the proportion of patients who received
26
27
28 a health checkup or the proportion of elderly persons per regional population (**Table 4**).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

In this cross-sectional ecological study, we demonstrated substantial regional variations in Japanese IgAN patient clinical characteristics at the diagnostic renal biopsy, including eGFR and the UPE rate. In addition, a lower number of board-certified nephrologists per regional population was closely associated with the clinical severity of IgAN, including the rate of fulfilment of clinical criteria for a very high risk renal prognosis.

Previous studies have shown apparent regional and national differences in CKD and ESRD incidence in the United States and Europe [30-32]. However, race and ethnicity within a study population must be homogenous to isolate the effects of social factors on regional differences in clinical factors. The Japanese population is useful for the evaluation of such factors, which may influence disease prevalence and severity, because of its ethnic homogeneity. Usami et al. demonstrated significant regional differences in the incidence of ESRD within Japan [33]. Studies of the ethnically homogenous Japanese population suggest that social factors, i.e., factors other than those with a genetic basis, contribute to such regional differences in the presentation of renal diseases. Similarly, our results pertaining to apparent regional differences in the clinical features of Japanese IgAN patients at biopsy diagnosis also suggest that such regional variation is due to social rather than genetic factors.

1
2
3
4 This is the first reported study to reveal regional differences in the clinical severity of IgAN
5
6
7 patients at biopsy diagnosis in Japan. Interestingly, the proportion of IgAN patients fulfilling the
8
9
10 clinical criteria for a very-high-risk renal prognosis at biopsy diagnosis showed an up to 3.7-fold
11
12
13 difference among the 10 regions. Studies on the natural history of IgAN have consistently identified
14
15
16 renal impairment and severe proteinuria as clinically detectable poor prognostic indicators at the time
17
18
19 of biopsy diagnosis [3-5]. In addition, such predictors of the progression to ESRD in patients with
20
21
22 IgAN are closely associated with pre-existing histopathological findings of advanced chronic renal
23
24
25 disease [34]. Thus, our current results showing a significant association between the number of
26
27
28 nephrologists per regional population and the clinical severity of IgAN patients at biopsy diagnosis
29
30
31 suggest a possible contribution of nephrologist availability to the likelihood of early diagnosis. The
32
33
34 uneven regional distribution of nephrologists may influence the time taken for referral from a
35
36
37 primary care physician to a nephrologist, who then decides regarding performance of a renal biopsy
38
39
40 and the therapeutic intervention.
41
42
43

44 Other than the number of nephrologists, several other socioeconomic factors may influence
45
46
47 the clinical severity of IgAN. Due to the universal health insurance coverage was established in 1961
48
49
50 in Japan, the gap between individuals with a poor medical economic status and the rest of the
51
52
53 population is reportedly lower than that in other countries [35]. The rate of health checkups may be
54
55
56
57
58
59
60

1
2
3
4 another important social factor influencing IgAN severity. Although urinalysis screening is popular
5
6
7 for school-age children, adult participation in such schemes can show significant variation among
8
9
10 regions in Japan. However, we did not find any significant effect of health checkup rate on the
11
12
13 severity of IgAN at biopsy diagnosis. One possible interpretation of this result is that referral to a
14
15
16 nephrologist may play a more important role than health checkups in IgAN severity. The proportion
17
18
19 of elderly persons in urban and rural populations differs significantly among regions in Japan, a
20
21
22 country in which there has been remarkable aging of rural populations, particularly in recent years.
23
24
25 Previous studies have suggested that elderly patients with IgAN have relatively more severe clinical
26
27
28 features at the time of diagnosis than do non-elderly patients [36,37]. Thus, we examined the effect
29
30
31 of regional variation in the proportion of elderly persons on the clinical severity of IgAN. However,
32
33
34 contrary to our expectations, we did not find any significant effect of the proportion of elderly
35
36
37 persons on the severity of IgAN at biopsy diagnosis. Referral to a nephrologist and renal biopsy may
38
39
40 be performed less often in elderly patients.
41
42
43

44 Our study had several important limitations. First, there were differences in both the number
45
46
47 of J-RBR registration facilities and the sample size among regions. Second, there may have been
48
49
50 differences in the criteria for performing renal biopsies among facilities. Because no formal criteria
51
52
53 for performing a renal biopsy are defined in the registry, all renal biopsies were performed at the
54
55
56
57

1
2
3
4 discretion of the attending physician. This may have influenced the regional differences in severity
5
6
7 of clinical features at the time of biopsy. Third, we could not exclude the potential influence of other
8
9
10 social factors, such as dietary habits or climatic factors, on the regional variation in clinical features
11
12
13 of IgAN patients. Fourth, the J-RBR does not include histopathological findings of renal biopsies.
14
15
16 Thus, we could not demonstrate that the clinical severity of the IgAN patients correlated with the
17
18
19 histopathological findings. Fifth, the applicability of the findings to countries other than Japan is
20
21
22 unclear. Since Japan is one of only a few countries in the world that screen for kidney diseases by
23
24
25 urinalysis. Finally, this study used a cross-sectional ecological design. Therefore, further studies are
26
27
28 required to elucidate the relationship between the number of nephrologists per regional population
29
30
31 and the renal prognosis of patients with IgAN.
32
33
34
35
36
37

38 **Conclusions**

39
40
41 This study identified considerable regional differences in the clinical severity of IgAN at the
42
43
44 biopsy diagnosis in Japanese patients. Our results suggest that an uneven distribution of
45
46
47 nephrologists across regions may influence the timing of nephrologist referral and biopsy diagnosis,
48
49
50 as well as the likelihood of earlier intervention to prevent progression to ESRD in patients with
51
52
53 IgAN.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 **Acknowledgments:** The authors gratefully acknowledge the help collecting data for the J-RBR and
5
6
7 the assistance of many colleagues in centers and affiliate hospitals. We also sincerely thank Ms. M.
8
9
10 Irie of UMIN-INDICE and Ms. Y. Saito of JSN for supporting the registration system.
11
12
13
14
15

16 **Author Contributions:** Research idea and study design: YO, NT, YM, TK, MO, TY; data
17
18 acquisition: YO, NT, IN, TN, HY; data analysis/interpretation: YO, NT; statistical analysis: YO, NT,
19
20
21 HA, TN; supervision or mentorship: NT, TY. Each author contributed important intellectual content
22
23 during manuscript drafting or revision and accepts accountability for the overall work by ensuring that
24
25
26 questions pertaining to the accuracy or integrity of any portion of the work are appropriately
27
28
29 investigated and resolved.
30
31
32
33
34
35
36
37

38 **Funding:** The study was supported in part by the committee grant from the Japanese Society of
39
40
41 Nephrology.
42
43
44
45
46
47

48 **Conflict of Interest Statement:** None declared.
49
50
51
52
53

54 **Patient consent:** Not required.
55
56
57
58
59
60

1
2
3
4
5
6
7 **Ethics approval:** All procedures performed in studies involving human participants were in
8
9
10 accordance with the ethical standards of the institutional and/or national research committee at which
11
12
13 the studies were conducted (IRB approval number: the Japanese Society of Nephrology, No. 27,
14
15
16 January 19, 2016) and with the 1964 Helsinki declaration and its later amendments, or comparable
17
18
19 ethical standards.
20
21
22
23
24
25

26 **Data sharing statement:** No additional data available.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. *Q J Med.* 1987;**64**:709–727. <https://doi.org/10.1093/oxfordjournals.qjmed.a068143>
2. Wyatt R, Julian B. IgA Nephropathy. *New Engl J Medicine* 2013;**368**:2402–2414. doi:10.1056/NEJMra1206793
3. Radford M, Donadio J, Bergstralh E, Grande J. Predicting renal outcome in IgA nephropathy. *J Am Soc Nephrol.* 1997;**8**:199–207.
4. Berthoux F, Mohey H, Laurent B, et al. Predicting the Risk for Dialysis or Death in IgA Nephropathy. *J Am Soc Nephrol* 2011;**22**:752–761. doi:10.1681/ASN.2010040355
5. Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. *Am J Kidney Dis* 2012;**59**:865–73. doi:10.1053/j.ajkd.2012.02.326
6. Manno C, Strippoli GF, D'Altri C, et al. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. *Am J Kidney Dis* 2007;**49**:763–75. doi:10.1053/j.ajkd.2007.03.013
7. Duan Z-YY, Cai G-YY, Chen Y-ZZ, et al. Aging promotes progression of IgA nephropathy: a systematic review and meta-analysis. *Am J Nephrol* 2013;**38**:241–52. doi:10.1159/000354646

- 1
2
3
4 8. Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA
5
6
7 nephropathy: results from a cohort of 1155 cases in a Chinese adult population. *Nephrol Dial*
8
9
10 *Transplant* 2012;**27**:1479–85. doi:10.1093/ndt/gfr527
11
12
- 13 9. Korbet SM, Genchi RM, Borok RZ, et al. The racial prevalence of glomerular lesions in
14
15
16 nephrotic adults. *Am J Kidney Dis* 1996;**27**:647–51. doi:10.1016/S0272-6386(96)90098-0
17
18
- 19 10. Pontier P, Patel T. Racial differences in the prevalence and presentation of glomerular disease in
20
21
22 adults. *Clin Nephrol.* 1994;**42**:79-84.
23
24
- 25 11. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy
26
27
28 worldwide. *Am J Med* 1990;**89**:209–15. doi:10.1016/0002-9343(90)90300-3
29
30
31
- 32 12. Fischer EG, Harris AA, Carmichael B, Lathrop SL, Cerilli LA. IgA nephropathy in the triethnic
33
34
35 population of New Mexico. *Clin Nephrol.* 2009;**72**:163–169. doi:10.2379/CN106139
36
37
- 38 13. Kiryluk K, Novak J, Gharavi AG. Pathogenesis of immunoglobulin A nephropathy: recent
39
40
41 insight from genetic studies. *Annu Rev Med* 2013;**64**:339–56.
42
43
44 doi:10.1146/annurev-med-041811-142014
45
46
- 47 14. Feehally J, Farrall M, Boland A, et al. HLA has strongest association with IgA nephropathy in
48
49
50 genome-wide analysis. *J Am Soc Nephrol* 2010;**21**:1791–7. doi:10.1681/ASN.2010010076
51
52
53
54
55
56
57

- 1
2
3
4 15. Kiryluk K, Li Y, Sanna-Cherchi S, *et al.* Geographic differences in genetic susceptibility to IgA
5
6 nephropathy: GWAS replication study and geospatial risk analysis. *PLoS*
7
8
9
10 *Genet* 2012;**8**:e1002765. doi:10.1371/journal.pgen.1002765
11
12
- 13 16. Szeto CC, Lai FM, To KF, *et al.* The natural history of immunoglobulin a nephropathy among
14
15 patients with hematuria and minimal proteinuria. *Am J Med* 2001;**110**:434–7.
16
17 doi:10.1016/S0002-9343(01)00659-3
18
19
20
21
- 22 17. Yamagata K, Iseki K, Nitta K, *et al.* Chronic kidney disease perspectives in Japan and the
23
24 importance of urinalysis screening. *Clin Exp Nephrol* 2008;**12**:1–8.
25
26
27 doi:10.1007/s10157-007-0010-9
28
29
30
31
- 32 18. Yamagata K, Takahashi H, Tomida C, Yamagata Y, Koyama A. Prognosis of asymptomatic
33
34 hematuria and/or proteinuria in men. High prevalence of IgA nephropathy among proteinuric
35
36 patients found in mass screening. *Nephron*. 2002;**91**:34–42. doi: 10.1159/000057602
37
38
39
40
- 41 19. Geddes CC, Rauta V, Gronhagen-Riska C, *et al.* A tricontinental view of IgA
42
43 nephropathy. *Nephrol Dial Transplant* 2003;**18**:1541–8. doi:10.1093/ndt/gfg207
44
45
46
- 47 20. Yamaguchi-Kabata Y, Nakazono K, Takahashi A, *et al.* Japanese population structure, based on
48
49 SNP genotypes from 7003 individuals compared to other ethnic groups: effects on
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 population-based association studies. *Am J Hum Genet* 2008;**83**:445–56.

5
6
7 doi:10.1016/j.ajhg.2008.08.019
8
9

- 10 21. Sugiyama H, Yokoyama H, Sato H, *et al.* Japan Renal Biopsy Registry: the first nationwide,
11
12 web-based, and prospective registry system of renal biopsies in Japan. *Clin Exp*
13
14
15
16
17 *Nephrol* 2011;**15**:493–503. doi:10.1007/s10157-011-0430-4
18
- 19 22. Churg J, Bernstein J, Glassock RJ, eds. *Renal disease, classification and atlas of glomerular*
20
21
22
23 *disease*. 2nd ed. Igaku-Shoin: Tokyo; 1995.
24
- 25 23. Matsuo S, Imai E, Horio M, *et al.* Revised equations for estimated GFR from serum creatinine
26
27
28
29 in Japan. *Am J Kidney Dis* 2009;**53**:982–92. doi:10.1053/j.ajkd.2008.12.034
30
31
- 32 24. Shimamoto K, Ando K, Fujita T, *et al.* The Japanese society of hypertension guidelines for the
33
34
35 management of hypertension (JSH 2014). *Hypertens Res.* 2014;**37**:253–390. doi :
36
37
38 10.1038/hr.2014.20
39
40
- 41 25. World Health Organization: Good health adds life to years. Global brief for World Health Day
42
43
44 2012. http://apps.who.int/iris/bitstream/10665/70853/1/WHO_DCO_WHD_2012.2_eng.pdf.
45
46
47
48 Accessed May 19, 2018.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 26. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
5
6
7 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney*
8
9
10 *Int Suppl.* 2013;**3**:1–150. doi:10.1038/kisup.2012.73.
11
12
13 27. Tomino Y. Diagnosis and treatment of patients with IgA nephropathy in Japan. *Kidney Res Clin*
14
15
16 *Pract.* 2016;**35**:197–203. doi : 10.1016/j.krcp.2016.09.001
17
18
19 28. Specific health checkups and specific guidance. Ministry of Health, Labour and Welfare
20
21
22 website. <http://www.mhlw.go.jp/english/wp/wp-hw3/dl/2-007.pdf>. Accessed May 19, 2018.
23
24
25 29. Population of Japan. Current Population Estimates as of October 1, 2012. Statistic Bureau,
26
27
28 Ministry of Internal Affairs and Communications website.
29
30
31 <http://www.stat.go.jp/english/data/jinsui/2012np/index.htm#a15k24-a>. Accessed May 19, 2018.
32
33
34 30. Tanner, R. M. *et al.* Geographic variation in CKD prevalence and ESRD incidence in the United
35
36
37 States: results from the reasons for geographic and racial differences in stroke (REGARDS)
38
39
40 study. *Am. J. Kidney Dis.* **61**, 395–403 (2013).
41
42
43
44 31. Dijk PC van, Jager KJ, Charro F de, *et al.* Renal replacement therapy in Europe: the results of a
45
46
47 collaborative effort by the ERA-EDTA registry and six national or regional registries. *Nephrol*
48
49
50 *Dial Transplant*2001;**16**:1120–9. doi:10.1093/ndt/16.6.1120
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 32. Brück K, Stel VS, Gambaro G, *et al.* CKD Prevalence Varies across the European General
5
6
7 Population. *J Am Soc Nephrol*2016;**27**:2135–47. doi:10.1681/ASN.2015050542
8
9
10 33. Usami T, Koyama K, Takeuchi O, *et al.*Regional variations in the incidence of end-stage renal
11
12
13 failure in Japan. *JAMA*2000;**284**:2622–4. doi:10.1001/jama.284.20.2622
14
15
16 34. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244
17
18
19 cases. *Am J Kidney Dis* 1997;**29**:829–42. doi:10.1016/S0272-6386(97)90456-X
20
21
22 35. Abe S. Japan’s vision for a peaceful and healthier world. *Lancet* 2015;**386**:2367–9.
23
24
25 doi:10.1016/S0140-6736(15)01172-1
26
27
28 36. Frimat L, Hestin D, Aymard B, *et al.* IgA nephropathy in patients over 50 years of age: a
29
30
31 multicentre, prospective study.*Nephrol Dial Transplant* 1996;**11**:1043–7.
32
33
34 doi:10.1093/oxfordjournals.ndt.a027453
35
36
37 37. Okabayashi Y, Tsuboi N, Haruhara K, *et al.* Reduction of proteinuria by therapeutic intervention
38
39
40 improves the renal outcome of elderly patients with IgA nephropathy. *Clin Exp Nephrol*
41
42
43 2016;**20**:910–917. doi:10.1007/s10157-016-1239-y
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Clinical characteristics of the patients at biopsy diagnosis.

Variables	Total (n=6426)	Hokkaido (n=148)	Tohoku (n=911)	Kanto (n=1229)	Koshinetsu (n=201)	Hokuriku (n=258)	Tokai (n=1432)	Kinki (n=706)	Chugoku (n=485)	Shikoku (n=183)	Kyushu (n=873)	p-value	Maximal fold among regions
Age, mean (SD), years	39.5 (17.7)	41.5 (16.6)	42.5 (18.1)	34.7 (17.5)	39.2 (14.9)	42.2 (16.8)	41.4 (16.6)	38.9 (17.1)	39.4 (17.8)	32.2 (20.2)	40.8 (18.3)	< 0.001	1.32
Male, no. (%)	3297 (51.3)	78 (52.7)	488 (53.6)	652 (53.1)	96 (47.8)	143 (55.4)	707 (49.4)	367 (52.0)	255 (52.6)	86 (47.0)	425 (48.7)	0.182	1.18
BMI mean (SD), kg/m ²	22.6 (4.0)	23.4 (4.2)	23.5 (4.2)	22.0 (4.2)	22.2 (3.7)	22.8 (3.6)	22.6 (3.7)	22.4 (4.1)	22.7 (4.2)	21.7 (4.0)	22.7 (4.0)	< 0.001	1.08
SBP, mean (SD), mm Hg	124 (18)	126 (19)	126 (17)	120 (18)	120 (16)	122 (17)	127 (18)	122 (18)	124 (18)	117 (16)	126 (19)	< 0.001	1.09
DBP, mean (SD), mm Hg	74 (13)	76 (13)	76 (13)	72 (13)	75 (13)	74 (13)	76 (13)	73 (12)	74 (13)	69 (12)	75 (13)	< 0.001	1.10
Hypertension, no. (%)	2790 (43.4)	82 (55.4)	403 (44.2)	457 (37.2)	93 (46.3)	127 (49.2)	709 (49.5)	279 (39.5)	203 (41.9)	49 (26.8)	388 (44.4)	< 0.001	2.07
eGFR, mean (SD), ml/min/1.73 m ²	74.4 (30.3)	67.5 (31.3)	73.3 (29.6)	79.6 (31.5)	71.3 (27.7)	73.2 (27.0)	69.0 (27.8)	74.8 (29.3)	78.0 (30.9)	91.4 (35.2)	73.5 (31.2)	< 0.001	1.35
Serum albumin, mean (SD), g/dl	3.9 (0.6)	3.7 (0.7)	4.0 (0.7)	4.0 (0.6)	4.0 (0.7)	3.8 (1.0)	3.9 (0.6)	3.9 (0.6)	4.0 (0.6)	4.0 (0.6)	3.9 (0.6)	< 0.001	1.08
Total cholesterol, mean (SD), mg/dl	194 (59)	198 (45)	182 (68)	186 (71)	188 (71)	198 (60)	204 (47)	199 (49)	197 (47)	189 (55)	198 (59)	< 0.001	1.12
UPE, mean (SD), g/day	1.16 (1.62)	1.93 (2.63)	1.00 (1.55)	0.97 (1.25)	0.93 (1.22)	1.00 (1.23)	1.42 (1.72)	1.04 (1.46)	0.97 (1.43)	1.08 (2.31)	1.35 (1.83)	< 0.001	2.08
Urinary RBC grade 3,4, No. (%)	4313 (67.1)	101 (68.2)	598 (65.6)	801 (65.2)	142 (70.6)	170 (65.9)	1024 (71.5)	454 (64.3)	327 (67.4)	94 (51.4)	602 (69.0)	< 0.001	1.39
KDIGO prognosis risk of CKD, no. (%)													
Very-high-risk	1813 (28.2)	59 (39.9)	265 (29.1)	289 (23.5)	61 (30.3)	64 (24.8)	495 (34.6)	175 (24.8)	117 (24.1)	20 (10.9)	268 (30.7)	< 0.001	3.66
High risk	2353 (36.6)	48 (32.4)	272 (29.9)	446 (36.3)	66 (32.8)	100 (38.8)	623 (43.5)	248 (35.1)	157 (32.4)	66 (36.1)	327 (37.5)	< 0.001	1.45
Moderately increased risk	1412 (22.0)	24 (16.2)	199 (21.8)	322 (26.2)	53 (26.4)	54 (20.9)	228 (15.9)	183 (25.9)	122 (25.2)	43 (23.5)	184 (21.1)	< 0.001	1.66
Low risk	849 (13.2)	17 (11.5)	175 (19.2)	172 (14.0)	21 (10.4)	40 (15.5)	86 (6.0)	100 (14.2)	89 (18.4)	54 (29.5)	94 (10.8)	< 0.001	4.92

BMI, body mass index; UPE, urinary protein excretion; RBC, red blood cells; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table 2. Regional variation in social factors.

Regions	Nephrologists, no. /100,000 populations	Proportion of participants who received a health checkup, %	Proportion of elderly persons relative to the general population, %
Hokkaido	1.58	36.7	27.1
Tohoku	2.75	46.5	27.3
Kanto	4.03	46.4	23.0
Koshinetsu	3.28	50.5	27.9
Hokuriku	4.26	48.7	27.2
Tokai	2.87	47.2	24.2
Kinki	3.47	40.7	25.2
Chugoku	3.08	41.1	27.8
Shikoku	3.07	43.1	29.1
Kyushu	3.21	43.2	26.3
Total mean	3.25	45.0	25.6
Maximal fold among regions	2.70	1.38	1.27
<i>p</i> -value	< 0.001	< 0.001	< 0.001

Table 3. Comparison of patient clinical characteristics among regions categorized according to the number of nephrologists.

Variables	Category of the number of nephrologists			<i>p</i> -value for trend
	Lowest three regions (n=2491)	Intermediate four regions (n=1742)	Highest three regions (n=2193)	
Nephrologists /100,000 population	2.75	3.17	3.87	
Age, mean (SD), year	41.8 (17.2)	39.3 (18.2)	36.9 (17.5)	< 0.001
Hypertension, no. (%)	1194 (47.9)	733 (42.1)	863(39.4)	< 0.001
eGFR, mean (SD), ml/min/1.73 m ²	70.5 (28.7)	77.3 (30.4)	77.3 (30.4)	< 0.001
UPE, mean (SD), g/day	1.30 (1.75)	1.17 (1.74)	0.99 (1.32)	< 0.001
KDIGO renal prognosis risk, no. (%)				
Very-high-risk	819 (32.9)	465 (26.7)	528 (24.1)	< 0.001
High risk	943 (37.9)	616 (35.4)	794 (36.2)	0.226
Moderately increased risk	451 (18.1)	402 (23.1)	559 (25.5)	< 0.001
Low risk	278 (11.2)	259 (14.9)	312 (14.2)	0.001

Table 4. Social factors and regional variation in IgAN patients with very-high-risk renal prognosis.

Fixed effects	f-value	Regression coefficient	95% CI	<i>p</i> -value
Number of nephrologists (/100,000 populations)	4.008	-0.484	-0.959 – -0.010	0.045
Proportion of patients who received a health checkup (%)	0.489	0.032	-0.057 – 0.120	0.485
Proportion of elderly persons relative to the general population (%)	3.510	-0.137	-0.281 – 0.006	0.061

95% CI, 95% confidence interval; Covariates: age, sex, hypertension; Random effects: region, J-RBR registration facility:

Structure for the random effects, First-order autoregressive.

Figure legends

Figure 1. Distributions of IgAN patients with a very-high-risk renal prognosis and of nephrologists.

Regional differences of the rate of IgAN patients with a very-high-risk renal prognosis at biopsy diagnosis, which was adjusted for age, sex, and hypertension (A), and the number of board-certified nephrologists per regional population (B). Based on the ranking of each factor, 10 regions of Japan were divided into three groups, as follows: the three lowest, four intermediate, and three highest groups. The numbers indicate the following regions: 1, Hokkaido; 2, Tohoku; 3, Kanto; 4, Koshinetsu; 5, Hokuriku; 6, Tokai; 7, Kinki; 8, Chugoku; 9, Shikoku; and 10, Kyushu.

Figure 2. Relationship between the rate of IgAN patients with a very-high-risk renal prognosis and the number of nephrologists per regional population.

Circles indicate each region and the areas of the circles are proportional to the regional populations. The rate of IgAN patients with a very-high-risk renal prognosis in each region was adjusted by age, sex, and hypertension. The regression line was obtained from the generalized linear mixed model in

Table 4.

1
2
3
4 **Supplementary Figure 1. Distributions of IgAN patients with a very-high-risk renal prognosis**
5
6
7 **and those of social factors other than nephrologist number.**
8
9

10 Regional differences in the rate of IgAN patients with a very-high-risk renal prognosis at biopsy
11
12 diagnosis, which was adjusted for age, sex, and hypertension (A), the rate of health checkup
13
14 participants per regional population (B), and the proportion of elderly persons per regional
15
16 population (C). Based on the ranking of each factor, 10 regions of Japan were divided into three
17
18 groups, as follows: the three lowest, four intermediate, and three highest groups. The numbers
19
20 indicate the following regions: 1, Hokkaido; 2, Tohoku; 3, Kanto; 4, Koshinetsu; 5, Hokuriku;
21
22
23
24
25
26
27
28
29 6, Tokai; 7, Kinki; 8, Chugoku; 9, Shikoku; and 10, Kyushu.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1

(A) IgAN with very-high-risk renal prognosis

(B) Nephrologists




Figure 1. Distributions of IgAN patients with a very-high-risk renal prognosis and of nephrologists.

Regional differences of the rate of IgAN patients with a very-high-risk renal prognosis at biopsy diagnosis, which was adjusted for age, sex, and hypertension (A), and the number of board-certified nephrologists per regional population (B). Based on the ranking of each factor, 10 regions of Japan were divided into three groups, as follows: the three lowest, four intermediate, and three highest groups. The numbers indicate the following regions: 1, Hokkaido; 2, Tohoku; 3, Kanto; 4, Koshinetsu; 5, Hokuriku; 6, Tokai; 7, Kinki; 8, Chugoku; 9, Shikoku; and 10, Kyushu.

190x107mm (300 x 300 DPI)




Figure 2. Relationship between the rate of IgAN patients with a very-high-risk renal prognosis and the number of nephrologists per regional population.


Circles indicate each region and the areas of the circles are proportional to the regional populations. The rate of IgAN patients with a very-high-risk renal prognosis in each region was adjusted by age, sex, and hypertension. The regression line was obtained from the generalized linear mixed model in **Table 4**.

190x107mm (300 x 300 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Supplementary Figure 1


(A) IgAN with a very-high-risk renal prognosis



(B) Health checkup participants



(C) Elderly population



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9, 10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	NA
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	12
		(b) Describe any methods used to examine subgroups and interactions	12
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	NA
		(b) Indicate number of participants with missing data for each variable of interest	NA
Outcome data	15*	Report numbers of outcome events or summary measures	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13
		(b) Report category boundaries when continuous variables were categorized	13
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	16-19
Generalisability	21	Discuss the generalisability (external validity) of the study results	19
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	21

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Distribution of nephrologists and regional variation in the clinical severity of IgA nephropathy at biopsy diagnosis in Japan: A cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024317.R1
Article Type:	Research
Date Submitted by the Author:	01-Oct-2018
Complete List of Authors:	Okabayashi, Yusuke; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine Tsuboi, Nobuo; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine Amano, Hoichi; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine Miyazaki, Yoichi; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine Kawamura, Tetsuya; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine Ogura, Makoto; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine Narita, Ichiei; Niigata University Medical and Dental Hospital, Department of Medicine (II) Toshiharu, N; Kyushu University, Fukuoka, Japan, Department of Epidemiology and Public Health Yokoyama, Hitoshi; Kanazawa Medical University School of Medicine Graduate School of Medicine Department of Nephrology, Department of Nephrology Yokoo, Takashi; Jikei University School of Medicine, Division of Nephrology and Hypertension, Department of Internal Medicine
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	Epidemiology
Keywords:	IgA nephropathy, renal biopsy, proteinuria, hematuria, chronic kidney disease, Glomerulonephritis < NEPHROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 1 **Distribution of nephrologists and regional variation in the clinical severity of IgA nephropathy**
5
6
7 2 **at biopsy diagnosis in Japan: A cross-sectional study**
8
9
10 3

11
12
13 4 Yusuke Okabayashi, MD¹; Nobuo Tsuboi, MD, PhD¹; Hoichi Amano, MD¹; Yoichi Miyazaki, MD,
14
15
16 5 PhD¹; Tetsuya Kawamura, MD, PhD¹; Makoto Ogura, MD, PhD¹; Ichiei Narita, MD, PhD²;
17
18
19 6 Toshiharu Ninomiya, MD, PhD³; Hitoshi Yokoyama, MD, PhD⁴; Takashi Yokoo, MD, PhD¹
20
21
22
23 7

24
25
26 8 ¹) Division of Nephrology and Hypertension, The Jikei University School of Medicine
27

28
29 9 ²) Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of
30
31
32 10 Medical and Dental Sciences
33

34
35 11 ³) Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu
36
37
38 12 University
39

40
41 13 ⁴) Department of Nephrology, Kanazawa Medical University School of Medicine
42
43
44
45 14

46
47
48 15 **Running title:** Regional variation of IgA nephropathy in Japan
49

50
51 16 **Word count:** 3349, abstract: 294
52
53
54
55
56
57

1
2
3
4 1 **Key words:** IgA nephropathy, renal biopsy, proteinuria, hematuria, chronic kidney disease,
5
6
7 2 glomerulonephritis
8
9

10 3 **Correspondence to:** Nobuo Tsuboi, M.D., Ph.D.
11
12

13 4 Division of Nephrology and Hypertension, Department of Internal Medicine,
14
15

16 5 The Jikei University School of Medicine, Tokyo 105-8641, Japan
17
18

19 6 3-25-8 Nishi-Shinbashi, Minato-Ku,
20
21

22 7 Tel: 81-3-3433-1111, Fax: 81-3-3433-4297, E-mail: tsuboi-n@jikei.ac.jp
23
24
25

26 8
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **1 Abstract**

5
6
7 **2 Objectives:** The clinical severity of IgA nephropathy (IgAN) at the time of biopsy diagnosis differs
8
9
10 significantly among cases. One possible determinant of any such difference is the time taken for
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
3 referral from the primary care physician to a nephrologist, but the definitive cause remains unclear.
4 This study examined the contribution of the number of nephrologists per regional population as a
5 potential social factor influencing the clinical severity at diagnosis among IgAN patients in Japan,
6 which has an ethnically homogeneous population.
7

8 Design: A cross-sectional study.

9 Setting & participants: Patients were registered in the Japan Renal Biopsy Registry (J-RBR), a
10 nationwide multicenter registry, and 6426 patients diagnosed with IgAN were analyzed. The
11 facilities registered to the J-RBR were divided into 10 regions and the clinical features of IgAN at
12 biopsy diagnosis, including renal function and level of proteinuria, were examined.

13 Main outcome measures: Renal prognosis risk at the time of biopsy diagnosis defined by Kidney
14 Disease Improving Global Outcomes guideline 2012.

15 Results: Among the regions, there were significant differences in the estimated glomerular filtration
16 rate (67.5–91.4 ml/min/1.73 m²), urinary protein excretion rate (0.93–1.93 g/day), and renal
17 prognosis risk group distribution at diagnosis. The severity of all clinical parameters was inversely

1 correlated with the number of nephrologists per regional population, which showed an up to 2.7-fold
2 difference among regions. A generalized linear mixed model revealed that a low number of
3 nephrologists per regional population was significantly associated with fulfillment of clinical criteria
4 indicating a very-high-risk renal prognosis ($\beta = -0.484$, 95% CI -0.959 to -0.010).

5 **Conclusions:** Among Japanese patients with IgAN, significant regional differences were detected in
6 clinical severity at the time of diagnosis. Social factors, such as an uneven distribution of
7 nephrologists across regions, may influence the timing of biopsy and determine such differences.

8

1
2
3
4 **1 Article Summary**
5

6
7 *2 Strengths and limitations of this study*
8

9
10 ● This study is based on the largest nationwide multicenter registry system of renal biopsies in
11
12
13 Japan.
14

15
16 ● The ethnically homogenous Japanese study population provides an opportunity to study the
17
18
19 influence of social factors on disease progression.
20

21
22 ● Because the registry system does not include detailed findings of renal biopsies, this study
23
24
25 cannot elucidate the association between the clinical severity and the histopathological grade.
26

27
28 ● Japan is one of only a few countries in the world that screens for kidney diseases by urinalysis,
29
30
31 thus the applicability of the findings to other countries is unclear.
32
33

34
35 11
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Introduction**

2 IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis and a
3 major cause of end-stage renal disease (ESRD) worldwide [1,2]. Impaired renal function and severe
4 proteinuria at presentation are among the strongest predictors of a poor renal prognosis in patients
5 with IgAN [3-5]. Advanced age, hypertension, male gender, obesity, and hematuria are considered
6 poor prognostic indicators, although controversy exists in the degree of involvement of these factors,
7 which varies by study depending on the subject characteristics [6-9]. Previous studies have shown
8 racial/ethnic differences in the prevalence of IgAN, and the relative number of patients diagnosed
9 with IgAN is higher in Asian countries than in other countries [10-12]. Recent genome-wide
10 analyses have demonstrated that genetic factors may underlie the diversity in the incidence and
11 severity of IgAN [13-16].

12 Except for cases showing gross hematuria, the onset of IgAN is often asymptomatic [17]. In
13 addition, IgAN cannot be diagnosed unless a renal biopsy is performed, as deposition of IgA in
14 glomeruli can be demonstrated histopathologically. Social factors, such as the penetration rate of
15 urinalysis screening for kidney disease or the time taken for referral from the primary care physician
16 to a nephrologist, may considerably influence the latency to IgAN diagnosis. In fact, in most patients
17 in Japan, potential cases of IgAN are first identified at a health checkup, followed by referral to a

1
2
3
4 1 nephrologist to assess the patient [18,19]. Such differences in survival related to the duration of
5
6
7 2 disease at time of presentation rather than true variability in disease severity is called lead-time bias,
8
9
10 3 and may also be associated with disease prognosis in IgAN patients [20].
11
12

13 4 Few studies have focused on regional variation in the clinical characteristics of IgAN [14,16].
14
15

16 5 In addition, other than race/ethnicity, no factors that may affect such regional variation in disease
17
18
19 6 severity have been determined. In this study, we analyzed clinical data of patients with IgAN in
20
21
22 7 Japan, which has an ethnically homogeneous population [21]. Social factors that may affect the
23
24
25
26 8 biopsy diagnosis of IgAN were examined in the context of potential differences in the clinical
27
28
29 9 severity of IgAN among various regions of Japan.
30
31
32 10
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Materials and Methods**

2 *Registry system and patient selection*

3 The Japan Renal Biopsy Registry (J-RBR) is a nationwide, multicenter registry system,
4 which was established in 2007 by the Committee for Standardization of Renal Pathological
5 Diagnosis and the Working Group for the Renal Biopsy Database of the Japanese Society of
6 Nephrology (JSN) [22]. The J-RBR includes the clinical records for all patients that underwent a
7 renal biopsy including the final renal histopathological diagnosis. However, the registry does not
8 include detailed histopathological findings. This cross-sectional study included Japanese patients
9 with primary IgAN registered on the J-RBR from January 1, 2007 through June 30, 2013. During the
10 registration period, 7,970 patients diagnosed with IgAN were included in the J-RBR. Of these 7,970
11 patients, 1,544 were excluded because of missing data critical for the analysis, such as renal function
12 measurements, the presence or absence of hypertension, and/or the urinary protein excretion (UPE)
13 rate. A total of 6,426 patients were finally subjected to the analysis. The diagnosis of IgAN was
14 histopathologically determined based on the basic glomerular changes described in the classification
15 of glomerular diseases of the World Health Organization, and by immunohistological identification
16 of IgA in glomeruli [23]. Patients who were diagnosed with other renal or systemic diseases,
17 including those with Henoch–Schönlein purpura, systemic lupus erythematosus, and liver cirrhosis

1 were excluded. Clinical data, including age, sex, body mass index (BMI), systolic and diastolic blood
2 pressure, the presence or absence of hypertension, estimated glomerular filtration rate (eGFR), UPE
3 rate, urinary sediment, serum albumin, and serum total cholesterol were evaluated. All clinical data
4 were obtained at the time of the diagnostic renal biopsy. The J-RBR is registered in the UMIN
5 Clinical Trials Registry (registered number: UMIN000000618).

7 *Measurements and definitions*

8 The J-RBR registration facilities were divided into 10 regions of Japan: Hokkaido, Tohoku,
9 Kanto, Koshinetsu, Hokuriku, Tokai, Kinki, Chugoku, Shikoku, and Kyusyu (**Figure 1**). The
10 Japanese populations in these regions are considered ethnically homogeneous [21].

11 The eGFR was calculated using a three-variable equation modified for Japanese populations,
12 as follows: $eGFR = 194 \times age^{-0.287} \times sCr^{-1.094}$ ($\times 0.739$ if female), where sCr is the serum creatinine
13 concentration [24]. Hematuria was defined as the number of red blood cells (RBCs) ≥ 5 per high
14 power field (HPF) in urinary sediment and graded based on the number of RBCs per HPF: 0, 1, 2,
15 and 3 for 0–4, 5–10, 11–30, and ≥ 30 , respectively. Hypertension was defined as a systolic blood
16 pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, according to the Japanese Society

1 of Hypertension Guidelines for the Management of Hypertension 2014 [25], or usage of
2 antihypertensive medications. Patients ≥ 65 years of age were defined as elderly [26].

3 In the Kidney Disease Improving Global Outcomes (KDIGO) 2012 clinical practice guideline
4 for the evaluation and management of chronic kidney disease, patients with chronic kidney disease
5 (CKD) are classified into 18 categories and four risk groups (low, moderately increased, high, and
6 very high risk) based on eGFR and albuminuria categories on a CKD heat map [27]. In Japan, this
7 CKD risk classification system has been modified according to the cause of kidney disease. Except
8 for diabetes cases, the UPE rate, instead of the urinary albumin excretion rate, is applied for patients
9 with CKD including IgAN, based on the requirements of the Japanese national insurance system
10 [28]. Based on the KDIGO 2012 guidelines, which were modified for the Japanese population, the
11 UPE rate at the time of biopsy is classified as normal (< 0.15 g/day or g/gCr; A1), mild (0.15–0.49
12 g/day or g/gCr; A2), or severe (≥ 0.5 g/day or g/gCr; A3) [27,28]. Similarly, eGFR at the time of
13 biopsy is classified into five groups: G1, G2, G3a, G3b, G4, and G5 for ≥ 90 , 60–89, 45–59, 30–44,
14 15–29, and < 15 ml/min/1.73 m², respectively. According to the CKD heat map of the 2012 KDIGO
15 guidelines, which is based on the eGFR level and UPE rate, the renal prognosis is categorized as
16 low, moderately increased, high, or very high.

1
2
3
4 1 *Social factors*
5
6

7 2 Certain social factors may be associated with regional variation in the clinical features of
8
9
10 3 IgAN. The first such factor is the number of board-certified JSN nephrologists per regional
11
12
13 4 population. A qualified JSN board-certified nephrologist must have ≥ 3 years training at a
14
15
16 5 JSN-accredited facility; have passed a specific exam; and renew their license every 5 years. The
17
18
19 6 second social factor is the proportion of participants who received a health checkup per regional
20
21
22 7 population. To ascertain this, we used data from the Specific Health Checkup, a metabolic syndrome
23
24
25 8 health checkup devised by the Ministry of Health, Labor, and Welfare of Japan that targets people
26
27
28 9 aged 40–74 years who were enrolled in the national health insurance program in 2012 [29]. The
29
30
31
32 10 Specific Health Checkup comprises a physical examination, blood pressure measurement, blood test,
33
34
35 11 and urinalysis. The third social factor is the proportion of elderly persons relative to the general
36
37
38 12 population. Information on the proportion of elderly persons (age ≥ 65 years) in each regional
39
40
41 13 population was obtained from a national survey performed in 2012 (**Supplementary table 1**) [30].
42
43
44 14 Based on the ranking of the social factors included in this study, 10 regions of Japan were divided
45
46
47 15 into three groups, as follows: low (three regions), intermediate (four regions), and high (three
48
49
50 16 regions) groups. Analysis was performed within each group according to the clinical characteristics
51
52
53 17 of the IgAN patients at the time of biopsy diagnosis.
54
55
56
57
58
59
60

1

2
3
4
5
6
7 2 *Statistical analysis*
8
9

10 3 Continuous variables are expressed as means \pm standard deviation. Differences among
11
12
13 4 regions were analyzed by the Kruskal–Wallis test. Differences in the characteristics of the IgAN
14
15
16 5 patients within each social factor group were analyzed by the Mantel–Haenszel test for trend and the
17
18
19 6 Jonckheere–Terpstra trend test, as appropriate. A generalized linear mixed model was constructed to
20
21
22 7 identify the social factors that may influence regional variation in the severity of IgAN at the time of
23
24
25 8 biopsy. In each analysis, social factors, age, sex, and the presence or absence of hypertension were
26
27
28 9 treated as fixed covariates, and the regions and the J-RBR registration facilities as random effects. A
29
30
31 10 p-value < 0.05 was considered significant. All statistical analyses were performed using SPSS
32
33
34 11 statistical software (ver. 24.0; IBM, Armonk, NY, USA).
35
36
37
38
39
40
41
42
43

44
45
46
47
48
49
50
51 13 *Patient and public involvement*
52
53
54
55
56
57
58
59
60

14 14 No patient was involved in the design or conduct of the study, since this was a database
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48 15 research study.
49
50
51
52
53
54
55
56
57
58
59
60

1 **Results**

2 *Patient clinical characteristics at the time of biopsy diagnosis*

3 The clinical characteristics of the patients at the time of biopsy diagnosis are summarized in

4 **Table 1.** A total of 1,813 (28.2%) patients were categorized into the very-high-risk renal prognosis

5 group. The male and female ratio was similar among the 10 regions. On the other hand, significant

6 regional variation was observed in age, BMI, prevalence of hypertension, eGFR, UPE rate, degree of

7 hematuria, and renal prognosis risk group distribution. Notably, there were large differences between

8 the lowest and highest regions with respect to the rates of both very high and low renal prognosis

9 risk, as defined by the KDIGO guidelines.

11 *Regional variation in social factors*

12 Variation among the 10 regions in terms of the social factors that may influence the severity

13 of IgAN at biopsy diagnosis were assessed (**Table 2**). The social factors included in this study were

14 the number of board-certified nephrologists, proportion of patients who received a health checkup,

15 and proportion of elderly persons per regional population. The distributions of these three social

16 factors differed significantly among the 10 regions. In particular, an up to 2.7-fold among regions

17 difference was observed in the number of board-certified nephrologists.

1
2
3
4 1
5
6
7 2 *Relationships between social factors and regional variation in the clinical characteristics of the*
8
9
10 3 *IgAN patients at biopsy diagnosis*
11
12

13 4 Trends in the social factors were analyzed according to regional variation in the clinical
14
15
16 5 features of the IgAN patients at biopsy diagnosis. The number of nephrologists per regional
17
18
19 6 population showed a clear trend: the fewer the nephrologists, the more severe were the clinical
20
21
22 7 features at the biopsy diagnosis, including renal function, the UPE rate, hematuria and the renal
23
24
25 8 prognosis risk distribution (**Table 3**). The regions with higher proportions of IgAN patients with a
26
27
28 9 very-high-risk renal prognosis and those with fewer nephrologists per regional population showed a
29
30
31 10 similar distribution trend (**Figure 1**). No such similarities were found between the distribution of
32
33
34 11 IgAN patients with a very-high-risk renal prognosis and those of health checkup participants or
35
36
37 12 elderly persons per regional population (**Supplemental Figure 1**).
38
39
40

41 13 A generalized linear mixed model was constructed to examine the relationship between the
42
43
44 14 three social factors investigated in this study and regional differences in the proportion of IgAN
45
46
47 15 patients with a very-high-risk renal prognosis at biopsy diagnosis, as defined by the 2012 KDIGO
48
49
50 16 guidelines. In the model, the number of board-certified nephrologists per regional population was
51
52
53 17 significantly associated with the rate of fulfilment of the clinical criteria for a very-high-risk renal
54
55
56
57
58
59
60

1
2
3
4 1 prognosis at the biopsy diagnosis, even after considering the differences in clinical factors among
5
6
7 2 regions (**Table 4, Figure 2**). We did not find a significant relationship between the rate of
8
9
10 3 very-high-risk renal prognosis at biopsy diagnosis and either the proportion of patients who received
11
12
13 4 a health checkup or the proportion of elderly persons per regional population (**Table 4**).
14
15
16 5

For peer review only

1 Discussion

2 In this cross-sectional study, we demonstrated substantial regional variations in Japanese
3 IgAN patient clinical characteristics at the diagnostic renal biopsy, including eGFR and the UPE rate.
4 In addition, a lower number of board-certified nephrologists per regional population was closely
5 associated with the clinical severity of IgAN, including the rate of fulfilment of clinical criteria for a
6 very high risk renal prognosis.

7 Previous studies have shown apparent regional and national differences in CKD and ESRD
8 incidence in the United States and Europe [31-33]. However, race and ethnicity within a study
9 population must be homogenous to identify the effects of social factors on regional differences in
10 clinical factors. The Japanese population is useful for the evaluation of such factors, which may
11 influence disease prevalence and severity, because of its ethnic homogeneity. Usami et al.
12 demonstrated significant regional differences in the incidence of ESRD within Japan [34]. Studies of
13 the ethnically homogenous Japanese population suggest that social factors, i.e., factors other than
14 those with a genetic basis, contribute to such regional differences in the presentation of renal
15 diseases. Similarly, our results pertaining to apparent regional differences in the clinical features of
16 Japanese IgAN patients at biopsy diagnosis also suggest that such regional variation is due to social
17 rather than genetic factors. However, the results reported here may not be applicable to individuals

1
2
3
4 1 living outside of Japan, since epigenetic and environmental factors also contribute to disease
5
6
7 2 progression.
8
9

10 3 This is the first reported study to reveal regional differences in the clinical severity of IgAN
11
12
13 4 patients at biopsy diagnosis in Japan. Interestingly, the proportion of IgAN patients fulfilling the
14
15
16 5 clinical criteria for a very-high-risk renal prognosis at biopsy diagnosis showed an up to 3.7-fold
17
18
19 6 difference among the 10 regions. Studies on the natural history of IgAN have consistently identified
20
21
22 7 renal impairment and severe proteinuria as clinically detectable poor prognostic indicators at the time
23
24
25 8 of biopsy diagnosis [3-5]. In addition, such predictors of the progression to ESRD in patients with
26
27
28 9 IgAN are closely associated with pre-existing histopathological findings of advanced chronic renal
29
30
31 10 disease [35]. Thus, our current results showing a significant association between the number of
32
33
34 11 nephrologists per regional population and the clinical severity of IgAN patients at biopsy diagnosis
35
36
37 12 suggest a possible contribution of nephrologist availability to the likelihood of early diagnosis. The
38
39
40 13 uneven regional distribution of nephrologists may influence the time taken for referral from a
41
42
43 14 primary care physician to a nephrologist, who then decides regarding performance of a renal biopsy
44
45
46 15 and the therapeutic intervention. The number of nephrologists practicing in Japan is comparable to
47
48
49 16 that of other developed countries. For example, in Japan there are 34 nephrologists per 1 million
50
51
52 17 population, comparable to the United States and Europe (28 and 31 per 1 million population,
53
54
55
56
57
58
59
60

1
2
3
4 1 respectively) [36]. However, the number of nephrologists per population in African and southeastern
5
6
7 2 Asian countries is much lower at 1–4 per 1 million population [36]. Further studies aimed at
8
9
10 3 understanding the demand and supply for nephrology workforce may help to explain the uneven
11
12
13 4 distribution of nephrologists.

14
15
16 5 Other than the number of nephrologists, several other socioeconomic factors may influence
17
18
19 6 the clinical severity of IgAN. Due to the universal health insurance coverage was established in 1961
20
21
22 7 in Japan, the gap between individuals with a poor medical economic status and the rest of the
23
24
25 8 population is reportedly lower than that in other countries [37]. The rate of health checkups may be
26
27
28 9 another important social factor influencing IgAN severity. Although urinalysis screening is
29
30
31 10 compulsory for school-age children, adult participation in such schemes can show significant
32
33
34 11 variation among regions in Japan. However, we did not find any significant effect of health checkup
35
36
37 12 rate on the severity of IgAN at biopsy diagnosis. One possible interpretation of this result is that
38
39
40 13 referral to a nephrologist may play a more important role than health checkups in IgAN severity. The
41
42
43 14 proportion of elderly persons in urban and rural populations differs significantly among regions in
44
45
46 15 Japan, a country in which there has been remarkable aging of rural populations, particularly in recent
47
48
49 16 years. Previous studies have suggested that elderly patients with IgAN have relatively more severe
50
51
52 17 clinical features at the time of diagnosis than younger patients [38,39]. Thus, we examined the effect
53
54
55
56
57
58
59
60

1
2
3
4 1 of regional variation in the proportion of elderly persons on the clinical severity of IgAN. However,
5
6
7 2 contrary to our expectations, we did not find any significant effect of the proportion of elderly
8
9
10 3 persons on the severity of IgAN at biopsy diagnosis. Referral to a nephrologist and renal biopsy may
11
12
13 4 be performed less often in elderly patients.

16 5 Our study had several important limitations. First, there were differences in both the number
17
18
19 6 of J-RBR registration facilities and the sample size among regions. Second, there may have been
20
21
22 7 differences in the criteria for performing renal biopsies among facilities. Because no formal criteria
23
24
25 8 for performing a renal biopsy are defined in the registry, all renal biopsies were performed at the
26
27
28 9 discretion of the attending physician. This may have influenced the regional differences in severity
29
30
31 10 of clinical features at the time of biopsy. Third, we could not exclude the potential influence of other
32
33
34 11 social factors, such as dietary habits or climatic factors, on the regional variation in clinical features
35
36
37 12 of IgAN patients. Fourth, the J-RBR does not include histopathological findings of renal biopsies.
38
39
40 13 Thus, we could not demonstrate that the clinical severity of the IgAN patients correlated with the
41
42
43 14 histopathological findings. Fifth, the applicability of the findings to countries other than Japan is
44
45
46 15 unclear: since Japan is one of only a few countries in the world that screen for kidney diseases by
47
48
49 16 urinalysis. Sixth, we did not fully evaluate hematuria in relation to clinical severity of IgAN.
50
51
52 17 Persistent hematuria in the presence of proteinuria is reportedly associated with the risk for
53
54
55
56
57
58
59
60

1 progression to ESRD in IgAN [9]. The CKD risk classification system of KDIGO 2012 does not
2 include hematuria [27,28] and the association between the degree of hematuria and clinical severity
3 of IgAN is unclear. Finally, it is a cross-sectional study. Therefore, further studies are required to
4 elucidate the relationship between the number of nephrologists per regional population and the renal
5 prognosis of patients with IgAN.

6 7 **Conclusions**

8 This study identified considerable regional differences in the clinical severity of IgAN at the
9 biopsy diagnosis in Japanese patients. Our results suggest that an uneven distribution of
10 nephrologists across regions may influence the timing of nephrologist referral and biopsy diagnosis,
11 as well as the likelihood of earlier intervention to prevent progression to ESRD in patients with
12 IgAN.

13

14

1
2
3
4 1 **Acknowledgments:** The authors gratefully acknowledge the help collecting data for the J-RBR and
5
6
7 2 the assistance of many colleagues in centers and affiliate hospitals. We also sincerely thank Ms. M.
8
9
10 3 Irie of UMIN-INDICE and Ms. Y. Saito of JSN for supporting the registration system.
11
12
13 4

15
16 5 **Author Contributions:** Research idea and study design: YO, NT, YM, TK, MO, TY; data
17
18
19 6 acquisition: YO, NT, IN, TN, HY; data analysis/interpretation: YO, NT; statistical analysis: YO, NT,
20
21
22 7 HA, TN; supervision or mentorship: NT, TY. Each author contributed important intellectual content
23
24
25 8 during manuscript drafting or revision and accepts accountability for the overall work by ensuring that
26
27
28 9 questions pertaining to the accuracy or integrity of any portion of the work are appropriately
29
30
31 10 investigated and resolved.
32
33
34
35 11

36
37
38 12 **Funding:** The study was supported in part by the committee grant from the Japanese Society of
39
40
41 13 Nephrology.
42
43
44 14

45
46
47 15 **Conflict of Interest Statement:** None declared.
48
49
50 16

51
52
53 17 **Patient consent:** Not required.
54
55
56
57
58
59
60

1
2
3
4 1
5
6
7 2 **Ethics approval:** All procedures performed in studies involving human participants were in
8
9
10 3 accordance with the ethical standards of the institutional and/or national research committee at which
11
12
13 4 the studies were conducted (IRB approval number: the Japanese Society of Nephrology, No. 27,
14
15
16 5 January 19, 2016) and with the 1964 Helsinki declaration and its later amendments, or comparable
17
18
19 6 ethical standards.
20
21
22
23 7
24
25
26 8 **Data sharing statement:** No additional data available.
27
28
29 9
30
31
32 10
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 1 **References**

- 2 1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. *Q J Med.*
3 1987;**64**:709–727. <https://doi.org/10.1093/oxfordjournals.qjmed.a068143>
- 4 2. Wyatt R, Julian B. IgA Nephropathy. *New Engl J Medicine* 2013;**368**:2402–2414.
5 doi:10.1056/NEJMra1206793
- 6 3. Radford M, Donadio J, Bergstralh E, Grande J. Predicting renal outcome in IgA nephropathy. *J*
7 *Am Soc Nephrol.* 1997;**8**:199–207.
- 8 4. Berthoux F, Mohey H, Laurent B, et al. Predicting the Risk for Dialysis or Death in IgA
9 Nephropathy. *J Am Soc Nephrol* 2011;**22**:752–761. doi:10.1681/ASN.2010040355
- 10 5. Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. *Am J Kidney Dis*
11 2012;**59**:865–73. doi:10.1053/j.ajkd.2012.02.326
- 12 6. Manno C, Strippoli GF, D'Altri C, et al. A novel simpler histological classification for renal
13 survival in IgA nephropathy: a retrospective study. *Am J Kidney Dis* 2007;**49**:763–75.
14 doi:10.1053/j.ajkd.2007.03.013
- 15 7. Duan Z-YY, Cai G-YY, Chen Y-ZZ, et al. Aging promotes progression of IgA nephropathy: a
16 systematic review and meta-analysis. *Am J Nephrol* 2013;**38**:241–52. doi:10.1159/000354646

- 1
2
3
4 1 8. Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA
5
6
7 2 nephropathy: results from a cohort of 1155 cases in a Chinese adult population. *Nephrol Dial*
8
9
10 3 *Transplant* 2012;**27**:1479–85. doi:10.1093/ndt/gfr527
11
12
13 4 9. Sevillano A, Gutiérrez E, Yuste C, et al. Remission of Hematuria Improves Renal Survival in
14
15
16 5 IgA Nephropathy. *J Am Soc Nephrol* 2017;**28**:3089–3099. doi:10.1681/ASN.2017010108
17
18
19 6 10. Korbet SM, Genchi RM, Borok RZ, et al. The racial prevalence of glomerular lesions in
20
21
22 7 nephrotic adults. *Am J Kidney Dis* 1996;**27**:647–51. doi:10.1016/S0272-6386(96)90098-0
23
24
25 8 11. Pontier P, Patel T. Racial differences in the prevalence and presentation of glomerular disease in
26
27
28 9 adults. *Clin Nephrol.* 1994;**42**:79-84.
29
30
31 10 12. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy
32
33
34 11 worldwide. *Am J Med* 1990;**89**:209–15. doi:10.1016/0002-9343(90)90300-3
35
36
37 12 13. Fischer EG, Harris AA, Carmichael B, Lathrop SL, Cerilli LA. IgA nephropathy in the triethnic
38
39
40 13 population of New Mexico. *Clin Nephrol.* 2009;**72**:163–169. doi:10.2379/CN106139
41
42
43 14 14. Kiryluk K, Novak J, Gharavi AG. Pathogenesis of immunoglobulin A nephropathy: recent
44
45
46 15 insight from genetic studies. *Annu Rev Med* 2013;**64**:339–56.
47
48
49 16 doi:10.1146/annurev-med-041811-142014
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 15. Feehally J, Farrall M, Boland A, *et al.* HLA has strongest association with IgA nephropathy in
5
6
7 2 genome-wide analysis. *J Am Soc Nephrol* 2010;**21**:1791–7. doi:10.1681/ASN.2010010076
8
9
10 3 16. Kiryluk K, Li Y, Sanna-Cherchi S, *et al.* Geographic differences in genetic susceptibility to IgA
11
12
13 4 nephropathy: GWAS replication study and geospatial risk analysis. *PLoS*
14
15
16 5 *Genet* 2012;**8**:e1002765. doi:10.1371/journal.pgen.1002765
17
18
19 6 17. Szeto CC, Lai FM, To KF, *et al.* The natural history of immunoglobulin a nephropathy among
20
21
22 7 patients with hematuria and minimal proteinuria. *Am J Med* 2001;**110**:434–7.
23
24
25 8 doi:10.1016/S0002-9343(01)00659-3
26
27
28
29 9 18. Yamagata K, Iseki K, Nitta K, *et al.* Chronic kidney disease perspectives in Japan and the
30
31
32 10 importance of urinalysis screening. *Clin Exp Nephrol* 2008;**12**:1–8.
33
34
35 11 doi:10.1007/s10157-007-0010-9
36
37
38 12 19. Yamagata K, Takahashi H, Tomida C, Yamagata Y, Koyama A. Prognosis of asymptomatic
39
40
41 13 hematuria and/or proteinuria in men. High prevalence of IgA nephropathy among proteinuric
42
43
44 14 patients found in mass screening. *Nephron*. 2002;**91**:34–42. doi: 10.1159/000057602
45
46
47
48 15 20. Geddes CC, Rauta V, Gronhagen-Riska C, *et al.* A tricontinental view of IgA
49
50
51 16 nephropathy. *Nephrol Dial Transplant* 2003;**18**:1541–8. doi:10.1093/ndt/gfg207
52
53
54
55
56
57
58
59
60

- 1
2
3
4 1 21. Yamaguchi-Kabata Y, Nakazono K, Takahashi A, *et al.* Japanese population structure, based on
5
6
7 2 SNP genotypes from 7003 individuals compared to other ethnic groups: effects on
8
9
10 3 population-based association studies. *Am J Hum Genet*2008;**83**:445–56.
11
12
13 4 doi:10.1016/j.ajhg.2008.08.019
14
15
16 5 22. Sugiyama H, Yokoyama H, Sato H, *et al.* Japan Renal Biopsy Registry: the first nationwide,
17
18
19 6 web-based, and prospective registry system of renal biopsies in Japan. *Clin Exp*
20
21
22 7 *Nephrol* 2011;**15**:493–503. doi:10.1007/s10157-011-0430-4
23
24
25 8 23. Churg J, Bernstein J, Glassock RJ, eds. *Renal disease, classification and atlas of glomerular*
26
27
28 9 *disease*. 2nd ed. Igaku-Shoin: Tokyo; 1995.
29
30
31
32 10 24. Matsuo S, Imai E, Horio M, *et al.* Revised equations for estimated GFR from serum creatinine
33
34
35 11 in Japan. *Am J Kidney Dis*. 2009;**53**:982–92. doi:10.1053/j.ajkd.2008.12.034
36
37
38 12 25. Shimamoto K, Ando K, Fujita T, *et al.* The Japanese society of hypertension guidelines for the
39
40
41 13 management of hypertension (JSH 2014). *Hypertens Res*. 2014;**37**:253–390. doi :
42
43
44 14 10.1038/hr.2014.20
45
46
47 15 26. World Health Organization: Good health adds life to years. Global brief for World Health Day
48
49
50 16 2012. http://apps.who.int/iris/bitstream/10665/70853/1/WHO_DCO_WHD_2012.2_eng.pdf.
51
52
53 17 Accessed May 19, 2018.
54
55
56
57
58
59
60

- 1
2
3
4 1 27. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
5
6
7 2 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney*
8
9
10 3 *Int Suppl.* 2013;**3**:1–150. doi:10.1038/kisup.2012.73.
11
12
13 4 28. Tomino Y. Diagnosis and treatment of patients with IgA nephropathy in Japan. *Kidney Res Clin*
14
15
16 5 *Pract.* 2016;**35**:197–203. doi : 10.1016/j.krcp.2016.09.001
17
18
19 6 29. Specific health checkups and specific guidance. Ministry of Health, Labour and Welfare
20
21
22 7 website. <http://www.mhlw.go.jp/english/wp/wp-hw3/dl/2-007.pdf>. Accessed May 19, 2018.
23
24
25 8 30. Population of Japan. Current Population Estimates as of October 1, 2012. Statistic Bureau,
26
27
28 9 Ministry of Internal Affairs and Communications website.
29
30
31
32 10 <http://www.stat.go.jp/english/data/jinsui/2012np/index.htm#a15k24-a>. Accessed May 19, 2018.
33
34
35 11 31. Tanner, R. M. *et al.* Geographic variation in CKD prevalence and ESRD incidence in the United
36
37
38 12 States: results from the reasons for geographic and racial differences in stroke (REGARDS)
39
40
41 13 study. *Am. J. Kidney Dis.* **61**, 395–403 (2013). doi: 10.1053/j.ajkd.2012.10.018.
42
43
44 14 32. Dijk PC van, Jager KJ, Charro F de, *et al.* Renal replacement therapy in Europe: the results of a
45
46
47 15 collaborative effort by the ERA-EDTA registry and six national or regional registries. *Nephrol*
48
49
50 16 *Dial Transplant*2001;**16**:1120–9. doi:10.1093/ndt/16.6.1120
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 1 33. Brück K, Stel VS, Gambaro G, *et al.* CKD Prevalence Varies across the European General
5
6
7 2 Population. *J Am Soc Nephrol* 2016;**27**:2135–47. doi:10.1681/ASN.2015050542
8
9
10 3 34. Usami T, Koyama K, Takeuchi O, *et al.* Regional variations in the incidence of end-stage renal
11
12
13 4 failure in Japan. *JAMA* 2000;**284**:2622–4. doi:10.1001/jama.284.20.2622
14
15
16 5 35. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244
17
18
19 6 cases. *Am J Kidney Dis* 1997;**29**:829–42. doi:10.1016/S0272-6386(97)90456-X
20
21
22 7 36. Sharif M, Elsayed M, Stack A. The global nephrology workforce: emerging threats and
23
24
25 8 potential solutions! *Clin Kidney J* 2016;**9**:11–22. doi:10.1093/ckj/sfv111
26
27
28 9 37. Abe S. Japan’s vision for a peaceful and healthier world. *Lancet* 2015;**386**:2367–9.
29
30
31 10 doi:10.1016/S0140-6736(15)01172-1
32
33
34
35 11 38. Frimat L, Hestin D, Aymard B, *et al.* IgA nephropathy in patients over 50 years of age: a
36
37
38 12 multicentre, prospective study. *Nephrol Dial Transplant* 1996;**11**:1043–7.
39
40
41 13 doi:10.1093/oxfordjournals.ndt.a027453
42
43
44 14 39. Okabayashi Y, Tsuboi N, Haruhara K, *et al.* Reduction of proteinuria by therapeutic intervention
45
46
47 15 improves the renal outcome of elderly patients with IgA nephropathy. *Clin Exp Nephrol*
48
49
50 16 2016;**20**:910–917. doi:10.1007/s10157-016-1239-y
51
52
53
54 17
55
56
57
58
59
60

Table 1. Clinical characteristics of the patients at biopsy diagnosis.

Variables	Total (n=6426)	Hokkaido (n=148)	Tohoku (n=911)	Kanto (n=1229)	Koshinetsu (n=201)	Hokuriku (n=258)	Tokai (n=1432)	Kinki (n=706)	Chugoku (n=485)	Shikoku (n=183)	Kyushu (n=873)	p-value	Maximal fold among regions
Age, mean (SD), years	39.5 (17.7)	41.5 (16.6)	42.5 (18.1)	34.7 (17.5)	39.2 (14.9)	42.2 (16.8)	41.4 (16.6)	38.9 (17.1)	39.4 (17.8)	32.2 (20.2)	40.8 (18.3)	< 0.001	1.32
Male, no. (%)	3297 (51.3)	78 (52.7)	488 (53.6)	652 (53.1)	96 (47.8)	143 (55.4)	707 (49.4)	367 (52.0)	255 (52.6)	86 (47.0)	425 (48.7)	0.182	1.18
BMI mean (SD), kg/m ²	22.6 (4.0)	23.4 (4.2)	23.5 (4.2)	22.0 (4.2)	22.2 (3.7)	22.8 (3.6)	22.6 (3.7)	22.4 (4.1)	22.7 (4.2)	21.7 (4.0)	22.7 (4.0)	< 0.001	1.08
SBP, mean (SD), mm Hg	124 (18)	126 (19)	126 (17)	120 (18)	120 (16)	122 (17)	127 (18)	122 (18)	124 (18)	117 (16)	126 (19)	< 0.001	1.09
DBP, mean (SD), mm Hg	74 (13)	76 (13)	76 (13)	72 (13)	75 (13)	74 (13)	76 (13)	73 (12)	74 (13)	69 (12)	75 (13)	< 0.001	1.10
Hypertension, no. (%)	2790 (43.4)	82 (55.4)	403 (44.2)	457 (37.2)	93 (46.3)	127 (49.2)	709 (49.5)	279 (39.5)	203 (41.9)	49 (26.8)	388 (44.4)	< 0.001	2.07
eGFR, mean (SD), ml/min/1.73 m ²	74.4 (30.3)	67.5 (31.3)	73.3 (29.6)	79.6 (31.5)	71.3 (27.7)	73.2 (27.0)	69.0 (27.8)	74.8 (29.3)	78.0 (30.9)	91.4 (35.2)	73.5 (31.2)	< 0.001	1.35
Serum albumin, mean (SD), g/dl	3.9 (0.6)	3.7 (0.7)	4.0 (0.7)	4.0 (0.6)	4.0 (0.7)	3.8 (1.0)	3.9 (0.6)	3.9 (0.6)	4.0 (0.6)	4.0 (0.6)	3.9 (0.6)	< 0.001	1.08
Total cholesterol, mean (SD), mg/dl	194 (59)	198 (45)	182 (68)	186 (71)	188 (71)	198 (60)	204 (47)	199 (49)	197 (47)	189 (55)	198 (59)	< 0.001	1.12
UPE, mean (SD), g/day	1.16 (1.62)	1.93 (2.63)	1.00 (1.55)	0.97 (1.25)	0.93 (1.22)	1.00 (1.23)	1.42 (1.72)	1.04 (1.46)	0.97 (1.43)	1.08 (2.31)	1.35 (1.83)	< 0.001	2.08
Hematuria grade 2,3, No. (%)	4313 (67.1)	101 (68.2)	598 (65.6)	801 (65.2)	142 (70.6)	170 (65.9)	1024 (71.5)	454 (64.3)	327 (67.4)	94 (51.4)	602 (69.0)	< 0.001	1.39
KDIGO prognosis risk of CKD, no. (%)													
Very-high-risk	1813 (28.2)	59 (39.9)	265 (29.1)	289 (23.5)	61 (30.3)	64 (24.8)	495 (34.6)	175 (24.8)	117 (24.1)	20 (10.9)	268 (30.7)	< 0.001	3.66
High risk	2353 (36.6)	48 (32.4)	272 (29.9)	446 (36.3)	66 (32.8)	100 (38.8)	623 (43.5)	248 (35.1)	157 (32.4)	66 (36.1)	327 (37.5)	< 0.001	1.45
Moderately increased risk	1412 (22.0)	24 (16.2)	199 (21.8)	322 (26.2)	53 (26.4)	54 (20.9)	228 (15.9)	183 (25.9)	122 (25.2)	43 (23.5)	184 (21.1)	< 0.001	1.66
Low risk	849 (13.2)	17 (11.5)	175 (19.2)	172 (14.0)	21 (10.4)	40 (15.5)	86 (6.0)	100 (14.2)	89 (18.4)	54 (29.5)	94 (10.8)	< 0.001	4.92

BMI, body mass index; UPE, urinary protein excretion; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table 2. Regional variation in social factors.

Regions	Nephrologists, no. /100,000 populations	Proportion of participants who received a health checkup, %	Proportion of elderly persons relative to the general population, %
Hokkaido	1.58	36.7	26.0
Tohoku	2.73	46.5	26.5
Kanto	4.03	46.4	22.1
Koshinetsu	3.26	50.5	27.0
Hokuriku	4.24	48.7	26.2
Tokai	2.87	47.2	23.3
Kinki	3.46	40.7	24.2
Chugoku	3.07	41.1	26.8
Shikoku	3.05	43.1	28.1
Kyushu	3.20	43.2	25.4
Total mean	3.40	45.0	24.2
Maximal fold among regions	2.68	1.38	1.27
<i>p</i> -value	< 0.001	< 0.001	< 0.001

Table 3. Comparison of patient clinical characteristics among regions categorized according to the number of nephrologists.

Variables	Category of the number of nephrologists			<i>p</i> -value for trend
	Lowest three regions (n=2491)	Intermediate four regions (n=1742)	Highest three regions (n=2193)	
Nephrologists /100,000 population	2.59	3.16	3.86	
Age, mean (SD), year	41.8 (17.2)	39.3 (18.2)	36.9 (17.5)	< 0.001
Hypertension, no. (%)	1194 (47.9)	733 (42.1)	863(39.4)	< 0.001
eGFR, mean (SD), ml/min/1.73 m ²	70.5 (28.7)	77.3 (30.4)	77.3 (30.4)	< 0.001
UPE, mean (SD), g/day	1.30 (1.75)	1.17 (1.74)	0.99 (1.32)	< 0.001
Hematuria grade 2 and 3, no (%)	1723 (69.2)	1165 (66.9)	1425 (65.0)	0.002
KDIGO renal prognosis risk, no. (%)				
Very-high-risk	819 (32.9)	465 (26.7)	528 (24.1)	< 0.001
High risk	943 (37.9)	616 (35.4)	794 (36.2)	0.226
Moderately increased risk	451 (18.1)	402 (23.1)	559 (25.5)	< 0.001
Low risk	278 (11.2)	259 (14.9)	312 (14.2)	0.001

Table 4. Social factors and regional variation in IgAN patients with very-high-risk renal prognosis.

Fixed effects	f-value	Regression coefficient	95% CI	<i>p</i> -value
Number of nephrologists (/100,000 populations)	4.022	-0.489	-0.967 – -0.011	0.045
Proportion of patients who received a health checkup (%)	0.521	0.033	-0.056 – 0.122	0.471
Proportion of elderly persons relative to the general population (%)	3.512	-0.140	-0.287 – 0.006	0.061

95% CI, 95% confidence interval; Covariates: age, sex, hypertension; Random effects: region, J-RBR registration facility:

Structure for the random effects, First-order autoregressive.

Figure legends

Figure 1. Distributions of IgAN patients with a very-high-risk renal prognosis and nephrologists.

Regional differences of the rate of IgAN patients with a very-high-risk renal prognosis at biopsy diagnosis, which was adjusted for age, sex, and hypertension (A), and the number of board-certified nephrologists per regional population (B). Based on the ranking of each factor, 10 regions of Japan were divided into three groups, as follows: the three lowest, four intermediate, and three highest groups. The numbers indicate the following regions: 1, Hokkaido; 2, Tohoku; 3, Kanto; 4, Koshinetsu; 5, Hokuriku; 6, Tokai; 7, Kinki; 8, Chugoku; 9, Shikoku; and 10, Kyushu.

Figure 2. Relationship between the rate of IgAN patients with a very-high-risk renal prognosis and the number of nephrologists per regional population.

Circles indicate each region and the areas of the circles are proportional to the regional populations. The rate of IgAN patients with a very-high-risk renal prognosis in each region was adjusted by age, sex, and hypertension. The regression line was obtained from the generalized linear mixed model in

Table 4.

1
2
3
4 **Supplementary Figure 1. Distributions of IgAN patients with a very-high-risk renal prognosis**
5
6
7 **and social factors other than nephrologist number.**
8
9

10 Regional differences in the rate of IgAN patients with a very-high-risk renal prognosis at biopsy
11
12 diagnosis, which was adjusted for age, sex, and hypertension (A), the rate of health checkup
13 participants per regional population (B), and the proportion of elderly persons per regional
14 population (C). Based on the ranking of each factor, 10 regions of Japan were divided into three
15
16 groups, as follows: the three lowest, four intermediate, and three highest groups. The numbers
17
18 indicate the following regions: 1, Hokkaido; 2, Tohoku; 3, Kanto; 4, Koshinetsu; 5, Hokuriku;
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Distributions of IgAN patients with a very-high-risk renal prognosis and of nephrologists.

Regional differences of the rate of IgAN patients with a very-high-risk renal prognosis at biopsy diagnosis, which was adjusted for age, sex, and hypertension (A), and the number of board-certified nephrologists per regional population (B). Based on the ranking of each factor, 10 regions of Japan were divided into three groups, as follows: the three lowest, four intermediate, and three highest groups. The numbers indicate the following regions: 1, Hokkaido; 2, Tohoku; 3, Kanto; 4, Koshinetsu; 5, Hokuriku; 6, Tokai; 7, Kinki; 8, Chugoku; 9, Shikoku; and 10, Kyushu.

190x107mm (300 x 300 DPI)




Figure 2. Relationship between the rate of IgAN patients with a very-high-risk renal prognosis and the number of nephrologists per regional population. † † Circles indicate each region and the areas of the circles are proportional to the regional populations. The rate of IgAN patients with a very-high-risk renal prognosis in each region was adjusted by age, sex, and hypertension. The regression line was obtained from the generalized linear mixed model in Table 4.

190x107mm (300 x 300 DPI)


Supplementary table 1. Regional populations and the number of nephrologists in Japan.

Regions	Populations (×1,000)	Number of nephrologists
Hokkaido	5460	86
Tohoku	9155	250
Kanto	42631	1719
Koshinetsu	5331	174
Hokuriku	3044	129
Tokai	15063	432
Kinki	20845	721
Chugoku	7504	230
Shikoku	3932	120
Kyushu	13144	421
Total	126109	4282


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Supplementary Figure 1


(A) IgAN with a very-high-risk renal prognosis



(B) Health checkup participants



(C) Elderly population



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9, 10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	NA
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	12
		(b) Describe any methods used to examine subgroups and interactions	12
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	NA
		(b) Indicate number of participants with missing data for each variable of interest	NA
Outcome data	15*	Report numbers of outcome events or summary measures	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13
		(b) Report category boundaries when continuous variables were categorized	13
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	16-19
Generalisability	21	Discuss the generalisability (external validity) of the study results	19
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	21

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.